Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$249K | -$1.57M | -$11.1M | -$7.31M | -$13.1M |
| Net income | -$248K | -$996K | -$11.1M | -$7.31M | -$13.1M |
| EPS (diluted) | — | — | -$36.35 | -$0.27 | -$0.35 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$316K | -$1.04M | -$1.34M | -$16.1M | -$1.79M |
| Share buybacks | — | — | — | $1.00M | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $479K | $40.8K | $2.48M | $917K | $1.38M |
| Total assets | $45.8M | $9.72M | $3.03M | $3.14M | $3.18M |
| Total liabilities | $1.62M | $2.65M | $9.77M | $3.00M | $13.5M |
| Shareholders' equity | $0.00 | -$1.04M | -$11.7M | $4.27M | -$10.4M |
| Retained earnings | -$1.01M | -$2.26M | -$12.2M | -$23.9M | -$37.0M |
| Shares (wtd avg diluted) | 1.18M | 1.42M | 306K | 27.1M | 36.8M |
Every figure is extracted from Estrella Immunopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.